Skip to main content
SpringerLink
Log in

Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Background

Primary hyperoxaluria (PH) results from genetic mutations in different genes of glyoxylate metabolism, which cause significant increases in production of oxalate by the liver. This study aimed to report clinical and laboratory manifestations and outcome of PH type 1 in children in our center.

Methods

A single-center observational cohort study was conducted at Children’s University Hospital in Damascus, and included all patients admitted from 2018 to 2020, with a diagnosis of hyperoxaluria (urinary oxalate excretion > 45 mg/1.73 m2/day, or > 0.5 mmol/1.73 m2/day). PH type 1 (PH1) diagnosis was established by identification of biallelic pathogenic variants (compound heterozygous or homozygous mutations) in AGXT gene on molecular genetic testing.

Results

The study included 100 patients with hyperoxaluria, with slight male dominance (57%), and median age 1.75 years (range, 1 month–14 years). Initial complaint was urolithiasis or nephrocalcinosis in 47%, kidney failure manifestations in 29%, and recurrent urinary tract infection in 24%. AGXT mutations were detected in 40 patients, and 72.5% of PH1 patients had kidney failure at presentation. Neither gender, age nor urinary oxalate excretion in 24 h had statistical significance in distinguishing PH1 from other forms of hyperoxaluria (P-Value > 0.05). Parental consanguinity, family history of kidney stones, bilateral nephrocalcinosis, presence of oxalate crystals in random urine sample, kidney failure and mortality were statistically significantly higher in PH1 (P-values < 0.05). Mortality was 32.5% among PH1 patients, with 4 PH1 patients (10%) on hemodialysis awaiting combined liver–kidney transplantation.

Conclusion

PH1 is still a grave disease with wide variety of clinical presentations which frequent results in delays in diagnosis, thus kidney failure is still a common presentation. In Syria, we face many challenges in diagnosis of PH, especially PH2 and PH3, and in management, with hopes that diagnosis tools and modern therapies will become available in our country.

A higher resolution version of the Graphical abstract is available as Supplementary information.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alon US, Srivastava T (2017) Urolithiasis in children. In: Kher KK, Schnaper HW, Greenbaum LA (eds) Clinical Pediatric Nephrology, 3rd edn. Boca Raton, pp 1014–1015

  2. Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M (2022) Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review. Am J Kidney Dis 79:717–727. https://doi.org/10.1053/j.ajkd.2021.07.018

    Article  CAS  PubMed  Google Scholar 

  3. Danpure CJ (2006) Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways. Biochim Biophys Acta 1763:1776–1784

    Article  CAS  PubMed  Google Scholar 

  4. Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P (2011) Primary hyperoxaluria. Int J Nephrol 2011:864580. https://doi.org/10.4061/2011/864580

    Article  CAS  Google Scholar 

  5. Milliner DS, Harris PC, Sas DJ, Cogal AG, Lieske JC (2002) Primary Hyperoxaluria Type 1. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds). GeneReviews® [Internet]. University of Washington, Seattle, Seattle, 1993–2022

  6. Weigert A, Martin-Higueras C, Hoppe B (2018) Novel therapeutic approaches in primary hyperoxaluria. Expert Opin Emerg Drugs 23:349–357. https://doi.org/10.1080/14728214.2018.1552940

    Article  CAS  PubMed  Google Scholar 

  7. Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB, Oosterveld MJS, Pelle A, Neuhaus T, Adams B, Cochat P, Salido E, Lipkin GW, Hoppe B, Hulton SA, OxalEurope Consortium (2019) Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int 96:1389–1399. https://doi.org/10.1016/j.kint.2019.08.018

    Article  CAS  PubMed  Google Scholar 

  8. Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B (2021) A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100:621–635. https://doi.org/10.1016/j.kint.2021.03.031

    Article  CAS  PubMed  Google Scholar 

  9. Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8:467–475. https://doi.org/10.1038/nrneph.2012.113

    Article  CAS  PubMed  Google Scholar 

  10. Hoppe B, Martin-Higueras C (2022) Improving Treatment Options for Primary Hyperoxaluria. Drugs 82:1077–1094. https://doi.org/10.1007/s40265-022-01735-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369:649–658. https://doi.org/10.1056/NEJMra1301564

    Article  CAS  PubMed  Google Scholar 

  12. Beck BB, Hoyer-Kuhn H, Göbel H, Habbig S, Hoppe B (2013) Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin Investig Drugs 22:117–129. https://doi.org/10.1517/13543784.2013.741587

    Article  CAS  PubMed  Google Scholar 

  13. Devresse A, Cochat P, Godefroid N, Kanaan N (2020) Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep 5:2136–2145. https://doi.org/10.1016/j.ekir.2020.09.022

    Article  PubMed  PubMed Central  Google Scholar 

  14. Metry EL, Garrelfs SF, Peters-Sengers H, Hulton SA, Acquaviva C, Bacchetta J, Beck BB, Collard L, Deschênes G, Franssen C, Kemper MJ, Lipkin GW, Mandrile G, Mohebbi N, Moochhala SH, Oosterveld MJS, Prikhodina L, Hoppe B, Cochat P, Groothoff JW, OxalEurope Consortium (2021) Long-term transplantation outcomes in patients with primary hyperoxaluria type 1 included in the European Hyperoxaluria Consortium (OxalEurope) registry. Kidney Int Rep 7:210–220. https://doi.org/10.1016/j.ekir.2021.11.006

    Article  PubMed  PubMed Central  Google Scholar 

  15. Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, van’t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216–1226. https://doi.org/10.1056/NEJMoa2021712

    Article  CAS  PubMed  Google Scholar 

  16. Hoppe B, Koch A, Cochat P, Garrelfs SF, Baum MA, Groothoff JW, Lipkin G, Coenen M, Schalk G, Amrite A, McDougall D, Barrios K, Langman CB (2022) Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int 101:626–634. https://doi.org/10.1016/j.kint.2021.08.015

    Article  CAS  PubMed  Google Scholar 

  17. Scott LJ, Keam SJ (2021) Lumasiran: first approval. Drugs 81:277–282. https://doi.org/10.1007/s40265-020-01463-0

    Article  CAS  PubMed  Google Scholar 

  18. Shee K, Stoller ML (2022) Perspectives in primary hyperoxaluria - historical, current and future clinical interventions. Nat Rev Urol 19:137–146. https://doi.org/10.1038/s41585-021-00543-4

    Article  PubMed  Google Scholar 

  19. Rhuma NR, Fituri OA, Sabei LT (2018) Mutational analysis of AGXT gene in Libyan children with primary hyperoxaluria type 1 at Tripoli Children Hospital. Saudi J Kidney Dis Transpl 29:30–38. https://doi.org/10.4103/1319-2442.225202

    Article  PubMed  Google Scholar 

  20. Nagara M, Tiar A, Ben Halim N, Ben Rhouma F, Messaoud O, Bouyacoub Y, Kefi R, Hassayoun S, Zouari N, Ben Ammar MS, Abdelhak S, Chemli J (2013) Mutation spectrum of primary hyperoxaluria type 1 in Tunisia: implication for diagnosis in North Africa. Gene 527:316–320. https://doi.org/10.1016/j.gene.2013.06.023

    Article  CAS  PubMed  Google Scholar 

  21. Guillaume A, Chiodini B, Adams B, Dahan K, Deschênes G, Ismaili K (2021) The struggling odyssey of infantile primary hyperoxaluria. Front Pediatr 9:615183. https://doi.org/10.3389/fped.2021.615183

    Article  PubMed  PubMed Central  Google Scholar 

  22. Soliman NA, Elmonem MA, Abdelrahman SM, Nabhan MM, Fahmy YA, Cogal A, Harris PC, Milliner DS (2022) Clinical and molecular characterization of primary hyperoxaluria in Egypt. Sci Rep 12:15886. https://doi.org/10.1038/s41598-022-17980-9

    Article  PubMed  PubMed Central  Google Scholar 

  23. Al Riyami MS, Al Ghaithi B, Al Hashmi N, Al Kalbani N (2015) Primary hyperoxaluria type 1 in 18 children: genotyping and outcome. Int J Nephrol 2015:634175. https://doi.org/10.1155/2015/634175

    Article  PubMed  PubMed Central  Google Scholar 

  24. Fadel FI, Kotb MA, Abdel Mawla MA, Hasanin RM, Salem AM, Fathallah MG, Amr KS, Ahmed HA, Salah DM (2022) Primary hyperoxaluria type 1 in children: clinical classification, renal replacement therapy, and outcome in a single centre experience. Ther Apher Dial 26:162–170. https://doi.org/10.1111/1744-9987.13666

    Article  CAS  PubMed  Google Scholar 

  25. Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC, Rare Kidney Stone Consortium (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570. https://doi.org/10.1681/ASN.2014070698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P, European Society for Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry (2012) Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 7:458–465. https://doi.org/10.2215/CJN.07430711

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS; IPHR Investigators (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493–2501. https://doi.org/10.1111/j.1600-6143.2010.03271.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bunchman TE, Swartz RD (1994) Oxalate removal in type I hyperoxaluria or acquired oxalosis using HD and equilibration PD. Perit Dial Int 14:81–84

    Article  CAS  PubMed  Google Scholar 

  29. Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF (2006) Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70:1642–1648. https://doi.org/10.1038/sj.ki.5001806

    Article  CAS  PubMed  Google Scholar 

  30. Hoppe B, Graf D, Offner G, Latta K, Byrd DJ, Michalk D, Brodehl J (1996) Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol 10:488–492. https://doi.org/10.1007/s004670050145

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

I would like to express my sincere gratitude to Dr. Hossam Murad, who performed the genetic analysis to our patients at Human Genetics Division, Molecular Biology and Biotechnology Department, Atomic Energy Commission of Syria.

Author information

Authors and Affiliations

  1. Faculty Member of Pediatric Nephrology in Faculty of Medicine, Damascus University, Damascus, Syria

    Hala Wannous

  2. Pediatric Nephrology, Hemodialysis, and Kidney Transplantation Department at Children’s University Hospital, Damascus University, Damascus, Syria

    Hala Wannous

Authors
  1. Hala Wannous
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hala Wannous.

Ethics declarations

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Competing interests

The author has no relevant financial or non-financial interests to disclose.

Conflict of interest

No conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Graphical Abstract (PPTX 49 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wannous, H. Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome. Pediatr Nephrol 38, 2643–2648 (2023). https://doi.org/10.1007/s00467-023-05917-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-023-05917-x

Keywords

Search

Navigation